CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR 10061|
|Strength||5, 10, 15, 25 mg capsules|
|Indication||Multiple Myeloma (newly diagnosed)|
|Funding Request||In combination with low-dose dexamethasone, for treatment of newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation|
|Review Status||Notification to Implement Issued|
|Pre Noc Submission||Yes|
|Submission Date||May 4, 2015|
|Submission Deemed Complete||May 11, 2015|
|Submission Type||New Indication|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||May 19, 2015|
|Check-point meeting||July 7, 2015|
|pERC Meeting||September 17, 2015|
|Initial Recommendation Issued||October 1, 2015|
|Feedback Deadline ‡||October 16, 2015|
|pERC Reconsideration Meeting||November 19, 2015|
|Final Recommendation Issued||December 3, 2015|
|Notification to Implement Issued||December 18, 2015|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.